Who can administer a vaccine?

Vaccines are prescription medicines, so they can only be administered by:

- a nurse practitioner
- a medical practitioner
- a registered midwife
- a designated prescriber (which includes a registered nurse fulfilling the designated prescriber criteria)
- a person authorised to administer the medicine in accordance with a prescription or a standing order.

In the case of an approved immunisation programme, vaccines can be administered without a prescription or standing order by:

- a person who is authorised by either the Director-General of Health or a medical officer of health under Regulation 44A of the Medicines Regulations 1984 (see Appendix 4).

Several vaccines have been considered by the Medicines Classification Committee and reclassified from prescription medicines to restricted medicines when administered by a registered pharmacist (who meets the conditions of the classification; see Appendix 4, ‘Pharmacist vaccinators’). It is the reclassification of a vaccine to a restricted medicine that gives a pharmacist vaccinator the authority to administer the vaccine without a prescription.

- See section 2.1 ‘Pre-vaccination’ for cold chain management, informed consent, pre-vaccination screening, contraindications, spacing of doses, catch-up, and adult vaccination.
- See section 2.2 ‘Vaccine administration’ for preparation, route, vaccination techniques by age, and multiple injections.
• See section 2.3 ‘Post-vaccination’ for post-vaccination advice, pain and fever recommendations, anaphylaxis and emergency management, and documentation and insurance.

2.1 Pre-vaccination

The ‘Immunisation standards for vaccinators’ and the ‘Guidelines for organisations storing vaccines and/or offering immunisation services’ apply to the delivery of all Schedule vaccines and those not on the Schedule. See Appendix 3.

The vaccinator is responsible for ensuring all the vaccines they are handling and administering have been stored at the recommended temperature range of +2°C to +8°C at all times (see ‘Cold chain management’ below and the National Standards for Vaccine Storage and Transportation for Immunisation Providers 2017). Information on vaccine presentation, preparation and disposal can be found in Appendix 7.

Vaccinators are expected to know and observe standard occupational health and safety guidelines in order to minimise the risk of spreading infection and needle-stick injury (see Appendix 7).

All vaccinations on the New Zealand National Immunisation Schedule are given parenterally (by injection) except for the rotavirus vaccine which is given non-parenterally (orally). For non-parenteral vaccine administration, follow the manufacturer’s instructions.

2.1.1 Cold chain management

All vaccines must be stored and/or transported within the recommended temperature range of +2°C to +8°C at all times. Refer to the National Standards for Vaccine Storage and Transportation for Immunisation Providers 2017 for detailed vaccine storage, transportation and destruction information.

The ‘cold chain’ is defined as ‘the system of transporting and storing vaccines within the recommended temperature range of +2°C to +8°C from the place of manufacture to the point of vaccine administration (the individual)’. The integrity of the cold chain is dependent not only on the equipment used for storage, transportation and monitoring but also on the people involved and the processes/practices they undertake.
Table 2.1: Key points for cold chain management

| All vaccinators are responsible for ensuring the vaccines they administer have been stored correctly. |
| All immunisation providers storing vaccines must use a pharmaceutical refrigerator. |
| The pharmaceutical refrigerator minimum and maximum temperatures must be monitored and recorded at the same time on a daily basis. |
| All immunisation providers must monitor the refrigerator with an electronic temperature recording device (eg, a data logger) that records and downloads data on a weekly basis. This should be compared with the daily minimum/maximum recordings. |
| All immunisation providers who store vaccines and/or offer immunisation services must achieve Cold Chain Accreditation. |
| Each immunisation provider must have a written cold chain management policy in place and ensure their policy is reviewed and updated annually. Each vaccinator is responsible to ensure they are able to access this policy, as it will contain important practice information on vaccine storage. |
| **If the vaccine refrigerator temperature goes outside the recommended +2°C to +8°C range** |
| • Label the vaccines ‘not for use’. |
| • If the refrigerator is currently running within the +2°C to +8°C range, leave the labelled vaccines in your refrigerator. |
| • If the refrigerator is not within the +2°C to +8°C range, pack your labelled vaccines into a chilly bin, with a temperature monitoring device and consider transporting to your back-up provider (details for this are in your cold chain policy). |
| • Download the data logger and check for inconsistencies or temperature fluctuations; note any temperature fluctuations outside the +2°C to +8°C range, and the time period. |
| • Contact your local immunisation coordinator for advice and further actions. |
| • Document the steps and actions you have taken. |

2.1.2 Informed consent

What is informed consent?

Informed consent is a fundamental concept in the provision of health care services, including immunisation. It is based on ethical obligations that are supported by legal provisions (eg, the Health and Disability Commissioner Act 1994, Code of Health and Disability Services Consumers’ Rights 1996, Health Information Privacy Code 1994, Privacy Act 1993 and Privacy Amendment Act 2013).
Providing meaningful information to enable an informed choice, and seeking informed consent, is a duty that all health and disability providers must meet to uphold the rights of health and disability consumers. Informed consent includes the right to be honestly and openly informed about one’s personal health matters. The right to agree to treatment carries with it the right to refuse and withdraw from treatment.

Informed consent is also an external expression of a health care provider’s pivotal ethical duty to uphold and enhance their patient’s autonomy by respecting the patient’s personhood in every aspect of their relationship with that individual.

**The informed consent process**

Informed consent is a process whereby the individual and/or their representative (if the individual does not have the capacity to consent) are appropriately informed in an environment and manner that are meaningful. Then, having been well informed, they are willing and able to agree to what is being suggested without coercion.

Regardless of age, an individual and/or their parent/guardian must be able to understand:

- that they have a choice
- why they are being offered the treatment/procedure
- what is involved in what they are being offered
- the probable benefits, risks, side-effects, failure rates and alternatives, and the risks and benefits of not receiving the treatment or procedure.

With regard to vaccination, the individual or parent/guardian needs to understand the benefits and risks of vaccination, including those to the child and community, in order to make an informed choice and give informed consent.

The essential elements of the informed consent process are effective communication, full information and freely given competent consent. The specific rights in the Code of Health and Disability Services Consumers’ Rights that represent these three elements are:
• Right 5: Right to effective communication
• Right 6: Right to be fully informed
• Right 7: Right to make an informed choice and give informed consent.²

For example, section 7(1) of the Code states that ‘services may be provided to a consumer only if that consumer makes an informed choice and gives informed consent, except where any enactment, or the common law, or any other provision of the Code provides otherwise.’ Information on the Code of Health and Disability Services Consumers’ Rights can be found on the Health and Disability Commissioner’s website (www.hdc.org.nz).

Health professionals have legal obligations to obtain informed consent prior to a procedure and prior to data collection (eg, data collected for the NIR). Unless there are specific legal exceptions to the need for consent, the health professional who acts without consent potentially faces the prospect of a civil claim for exemplary damages, criminal prosecution for assault (sections 190 and 196 of the Crimes Act 1961), complaints to the Health and Disability Commissioner, and professional disciplining.

Ensuring that an individual has made an informed choice regarding treatment options has been included in the Health Practitioners Competence Assurance Act 2003. This Act ensures that health practitioners are, and remain, competent and safe to practise. For example, the Nursing Council of New Zealand competencies for the Registered Nurse Scope of Practice, Competency 2.4, ‘ensures the client has adequate explanation of the effects, consequences and alternatives of proposed treatment options’ (see the Nursing Council of New Zealand website, www.nursingcouncil.org.nz).

**Privacy, and control over personal information**

The right to authorise, or to exert some control over, the collection and disclosure of personal information about oneself is a right closely allied to that of consent to treatment and is also relevant to personal integrity and autonomy. The Health Information Privacy Code 1994 gives people the right to access, and seek correction of, health information about them (Rules 6 and 7). It also requires health agencies collecting
identifiable information to be open about how and for what purpose that information will be stored, and who will be able to see it (Rule 3).

Parents and guardians have a similar right of access to information about their children under section 22F of the Health Act 1956. This right is limited in that access requests can be refused if providing the information would be contrary to the interests or wishes of the child.

Further information about privacy and health information can be found on the Privacy Commissioner’s website (www.privacy.org.nz), or by calling the privacy enquiries line: 0800 803 909.

Immunisation consent in primary care

Parents should be prepared during the antenatal period for the choice they will have to make about their child’s vaccination. During the third trimester of pregnancy, the lead maternity carer must provide Ministry of Health information on immunisation and the NIR. This is a requirement under clause DA21(c) of the Primary Maternity Services Notice 2007, pursuant to section 88 of the New Zealand Public Health and Disability Act 2000.

Vaccine hesitancy

Vaccine hesitancy refers to delay in acceptance or refusal of vaccines despite availability of vaccination services. Vaccine hesitancy is complex and context specific varying across time, place and vaccines. It includes factors such as complacency, convenience and confidence.

WHO: Addressing Vaccine Hesitancy (www.who.int/immunization/programmes_systems/vaccine_hesitancy/en/)

Effective communication and active listening are key components of the informed consent process, especially when health care providers are working with vaccine-hesitant individuals/parents/guardians.

- Be willing to initiate the conversation, avoid leaving it to others.
- Tailor content to the needs of the individual.
- Ensure respect and acknowledgement of concerns.
- Use plain language, open-ended questions and active listening.
- Avoid medical jargon, or ensure it is explained.
• Offer resources.
• Finish with an effective immunisation recommendation.

**Information for parents, guardians and health care providers**

Health care providers must offer information without individuals or parents/guardians having to ask for it. The depth of information offered or required may differ, but it should at least ensure that the individual or parent/guardian understands what the vaccine is for and the possible side-effects, as well as information about the vaccination programme, the NIR and the risks of not being vaccinated (see chapter 3).

Every effort should be made to ensure that the need for information is met, including extra discussion time, use of an interpreter and alternative-language pamphlets. (Ministry of Health immunisation pamphlets are produced in several languages, and are available from the local authorised provider or can be ordered, viewed and/or downloaded from the HealthEd website: [www.healthed.govt.nz](http://www.healthed.govt.nz))

Issues to discuss with individuals or parents/guardians about immunisation include:

- the vaccine-preventable diseases
- the vaccines used on the Schedule (ie, the funded vaccines that are available)
- how vaccines work, known risks and adverse events, and what the vaccine is made of, in case of known allergies
- the collection of immunisation information on the NIR from birth, or as part of a targeted immunisation programme (eg, the information that will be collected, who will have access to it and how it will be used; see section 2.3.5 for more information on the NIR)
- the choice to vaccinate.

Informed consent is required for each immunisation episode or dose. Presentation for an immunisation event should not be interpreted as implying consent. Individuals and parents/guardians have the right to change their mind at any time. Where consent is obtained formally but not in writing, the provider should document what was discussed, and that consent was obtained and by whom.
Ministry of Health information

Ministry of Health immunisation information for parents and guardians is available on the Ministry of Health’s website (www.health.govt.nz/immunisation). Parents and guardians may also order, view or download Ministry of Health immunisation information from the HealthEd website (www.healthed.govt.nz) or from the local authorised resource provider, including:

- Immunise Your Child on Time (leaflet, available in English [HE1327] and other languages)
- Childhood Immunisation (health education booklet [HE1323]).

Further immunisation consent information for health care providers is also available in Appendix 3 of this Handbook ‘Immunisation standards for vaccinators and Guidelines for organisations offering immunisation services’. Responses to commonly asked questions and suggestions for addressing myths and concerns are available in chapter 3 of this Handbook ‘Vaccination questions and addressing concerns’.

Other information sources

- The vaccine manufacturers’ data sheets, available on the Medsafe website (www.medsafe.govt.nz). Both consumer and health care provider versions are available.
- Other immunisation-related websites (see Appendix 9).

Alternatively, contact:

- the Immunisation Advisory Centre (IMAC) on freephone 0800 IMMUNE or (0800 466 863), or see the IMAC website (www.immune.org.nz)
- the immunisation coordinator (a list and contact details are available at www.immune.org.nz).
Immunisation consent in other settings (eg, schools)

In mass immunisation campaigns, such as those undertaken at schools, the consent requirements are different from those that apply to the vaccination of individuals in primary care. The parent/guardian may not be with the child on the day of immunisation, so immunisation should proceed only after the parent/guardian has had the opportunity to read the immunisation information and discuss any areas of concern. Consent forms are provided for immunisations given in schools by public health nurses. For children aged under 16 years who are being immunised at school, written consent must be obtained from the parent/guardian. Individuals who are aged 16 years or older may self-consent.

Consent and children

Under the Code of Rights, every consumer, including a child, has the right to the information they need to make an informed choice or to give informed consent. The law relating to the ability of children to consent to medical treatment is complex. There is no one particular age at which all children can consent to all health and disability services. The presumption that parental consent is necessary in order to give health care to those aged under 16 years is inconsistent with common law developments and the Code of Rights.

The Code of Rights makes a presumption of competence (to give consent) in relation to children, although New Zealand is unusual in this respect (ie, the obligations regarding consent of minors are greater in New Zealand than in many other jurisdictions).

A child aged under 16 years has the right to give consent for minor treatment, including immunisation, providing he or she understands fully the benefits and risks involved. In 2002 the Health and Disability Commissioner provided an opinion of a child’s consent to a vaccine, whereby the Commissioner was satisfied that a 14-year-old was competent to give informed consent for an immunisation event due to an injury where a tetanus toxoid vaccine would be commonly given. More details of this opinion can be found on the Health and Disability Commissioner’s website (www.hdc.org.nz – Case: 01HDC02915).

Further information on informed consent can be found on the Health and Disability Commissioner’s website (www.hdc.org.nz).
2.1.3  Pre-vaccination screening

Prior to immunisation with *any* vaccine, the vaccinator should ascertain if the vaccinee (child or adult) has a condition or circumstance which may influence whether a vaccine is given, deferred or contraindicated. Refer to Table 2.2 below, which provides a checklist of conditions or circumstances to screen for, along with the appropriate action to take and a rationale.

The vaccinator will also need to determine which vaccines the vaccinee is due to have, assess the vaccinee’s overall current vaccination status and address parental concerns. The vaccinator also needs to advise the individual/parent/guardian they will need to remain for 20 minutes post-vaccination.

Table 2.2: Pre-vaccination screening and actions to take

<table>
<thead>
<tr>
<th>Condition* or Circumstance</th>
<th>Action</th>
<th>Rationale</th>
</tr>
</thead>
<tbody>
<tr>
<td>Is unwell today:</td>
<td></td>
<td></td>
</tr>
<tr>
<td>• fever &gt;38°C</td>
<td>Defer all vaccines until afebrile. Note: Children with minor illnesses (without acute symptoms/signs) should be vaccinated.</td>
<td>To avoid an adverse event in an already unwell child, or to avoid attributing symptoms to vaccination.</td>
</tr>
<tr>
<td>• acute systemic illness</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Is a preterm infant and had apnoeas following immunisation in hospital (6-week and/or 3-month event)</td>
<td>Re-admission for the next infant immunisation and respiratory monitoring for 48 to 72 hours may be warranted, but do not avoid or delay immunisation.</td>
<td>There is a potential risk of apnoea in infants born before 28 weeks’ gestation.</td>
</tr>
<tr>
<td>Previously had a severe reaction to any vaccine</td>
<td>Careful consideration will be needed depending on the nature of the reaction. If in doubt about the safety of future doses, seek specialist advice.</td>
<td>Anaphylaxis to a previous vaccine dose or any component of the vaccine is an absolute contraindication to further vaccination with that vaccine.</td>
</tr>
</tbody>
</table>

*Continued overleaf*

---

<table>
<thead>
<tr>
<th>Condition* or Circumstance</th>
<th>Action</th>
<th>Rationale</th>
</tr>
</thead>
<tbody>
<tr>
<td>Anaphylaxis to vaccine components (eg, gelatin, egg protein, neomycin)</td>
<td>Refer to the relevant vaccine data sheet (<a href="http://www.medsafe.govt.nz">www.medsafe.govt.nz</a>) for the components. If an individual has had anaphylaxis to any component contained in a vaccine, seek specialist advice. Egg allergy, including anaphylactic egg allergy, is not a contraindication to MMR or influenza vaccination (see sections 10.6.3 and 11.6.3).</td>
<td>Vaccinators need to be aware of the possibility that allergic reactions, including anaphylaxis, may occur after any vaccination without any apparent risk factors (see section 2.3.3). Delayed hypersensitivity to a prior vaccine dose or a component of a vaccine is not a contraindication to further doses, but it is important to distinguish these from anaphylaxis.</td>
</tr>
<tr>
<td>Appropriate spacing between doses of the same vaccine (when was the last vaccination, and what was it?)</td>
<td>See section 2.1.5 and check the relevant disease chapters and catch-up schedules. (See below for live parenteral vaccines.)</td>
<td>The general rule is for a minimum of 4 weeks between doses of a primary series and 4 months between the priming dose(s) and the booster.</td>
</tr>
<tr>
<td>Had a live parenteral vaccine within the last 4 weeks – if in doubt, check the individual’s immunisation status on the NIR (if applicable)</td>
<td>Delay live attenuated parenteral vaccines to 4 weeks.</td>
<td>The antibody response to the first dose may interfere with the response to the second. They may be given on the same day without interference. Note that this does not apply to rotavirus vaccine, which is a non-parenteral vaccine.</td>
</tr>
<tr>
<td>Had an injection of immunoglobulin or a blood transfusion within the last 11 months and is now due for a live vaccine</td>
<td>Check which product the person received and the interval since administration, and refer to Table A6.1. Delay vaccination if necessary.</td>
<td>Live virus vaccines should be given at least 3 weeks before, or deferred for up to 11 months after, doses of human normal immunoglobulin or other blood products. The interval will be determined by the blood product and dose received.</td>
</tr>
</tbody>
</table>

*Continued overleaf*
<table>
<thead>
<tr>
<th>Condition* or Circumstance</th>
<th>Action</th>
<th>Rationale</th>
</tr>
</thead>
<tbody>
<tr>
<td>Has a disease that lowers immunity, is receiving treatment that lowers immunity or is an infant of a mother who received immunosuppressive therapy during pregnancy</td>
<td>See chapter 4 ‘Immunisation of special groups’. In some cases, specialist advice may need to be sought before vaccination. Note: Persons living with someone with lowered immunity should be vaccinated, including with live viral vaccines (see section 4.3.1).</td>
<td>The safety and effectiveness of the vaccine may be suboptimal in persons who are immunocompromised. Live attenuated vaccines may be contraindicated.</td>
</tr>
<tr>
<td>Is planning a pregnancy</td>
<td>See section 4.1.1 ‘For women planning pregnancy’. Ensure women and household members have received all vaccines recommended for their age group. Women should know if they are immune to rubella (section 18.5.3) and varicella (section 21.5.4). Advise women not to become pregnant within 4 weeks of receiving live viral vaccines.</td>
<td>Vaccinating before pregnancy may prevent maternal illness, which could affect the infant, and may confer passive immunity to the newborn.</td>
</tr>
<tr>
<td>Is pregnant</td>
<td>See sections 4.1.2 ‘During pregnancy’ and 4.1.3 ‘Breastfeeding and post-partum’. Influenza and Tdap vaccines are recommended. Live vaccines should be avoided until after the delivery.</td>
<td>Vaccinating (with inactivated vaccines) during pregnancy may prevent maternal illness, which could affect the infant, and may confer passive immunity to the newborn. Deferring administration of live vaccines until after delivery is a precautionary safety measure. Studies of women who inadvertently received a live vaccine during pregnancy and their infants have not identified any adverse effects.</td>
</tr>
</tbody>
</table>

Continued overleaf
<table>
<thead>
<tr>
<th>Condition* or Circumstance</th>
<th>Action</th>
<th>Rationale</th>
</tr>
</thead>
<tbody>
<tr>
<td>Undiagnosed or evolving neurological condition (for pertussis-containing vaccines only)</td>
<td>Seek specialist advice.</td>
<td>There is the potential for confusion about the role of vaccination in the context of a clinically unstable illness. The risks and benefits of withholding vaccination until the clinical situation has stabilised should be considered on an individual basis.</td>
</tr>
</tbody>
</table>
| Thrombocytopenia or bleeding disorders                                                     | Administer intramuscular vaccines with caution:  
  • use a 23-gauge or smaller needle and apply firm pressure to the injection site (without rubbing) for at least 10 minutes. | A haematoma may occur following intramuscular administration. The subcutaneous route is still recommended by some authorities – seek specialist advice when appropriate. |
| Individuals who are currently being treated with immune checkpoint inhibitors, as well as those who have discontinued treatment within the past 6 months. | Seek specialist advice.               | There is a theoretical risk that vaccines may trigger an autoimmune response in these individuals. See the ‘Oncology patients treated with immune checkpoint inhibitors’ discussion in section 4.3.3. |

* See chapter 4 ‘Immunisation of special groups’ for more information about pregnancy and lactation and for information about infants with special immunisation considerations, immune-deficient and immunosuppressed individuals, immigrants and refugees, travel, and occupational and other risk factors.

2.1.4 Contraindications

No individual should be denied vaccination without serious consideration of the consequences, both for the individual and for the community. Where there is any doubt, seek advice from the individual’s general practitioner (GP), a public health medicine specialist, medical officer of health, consultant paediatrician or IMAC.

Anaphylaxis to a previous vaccine dose or any component of the vaccine is an absolute contraindication to further vaccination with that vaccine. (Note that egg-related anaphylaxis and influenza or MMR vaccines are exceptions.) For more detail on anaphylaxis, see section 2.3.3.

Live viral vaccines should not be given to pregnant women, nor, in general, to immunosuppressed individuals (see chapter 4).

Seek specialist advice for individuals being treated with immune checkpoint inhibitors, as well as those who have discontinued treatment within the past 6 months. See ‘Oncology patients treated with immune checkpoint inhibitors’ in section 4.3.3.

See the relevant disease chapter section for more specific vaccine contraindications.

Conditions that are not contraindications to immunisation

The conditions in Table 2.3 are not contraindications to the immunisation of children and adults (see also section 3.1).
### Table 2.3: Conditions that are *not* contraindications to immunisation

Individuals with these conditions should be vaccinated with all the recommended vaccines.

<table>
<thead>
<tr>
<th>Condition</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mildly unwell, with a temperature $\leq 38^\circ C$</td>
</tr>
<tr>
<td>Asthma, hay fever, eczema, ‘snuffles’, allergy to house dust</td>
</tr>
<tr>
<td>Treatment with antibiotics or locally acting steroids</td>
</tr>
<tr>
<td>A breastfeeding mother or a breastfed child</td>
</tr>
<tr>
<td>Neonatal jaundice</td>
</tr>
<tr>
<td>Low weight in an otherwise healthy child</td>
</tr>
<tr>
<td>The child being over the usual age for immunisation – use age-appropriate vaccines, as per the catch-up schedules in Appendix 2 (the exception is rotavirus vaccine, see section 17.5.2)</td>
</tr>
<tr>
<td>A previous hypotonic-hyporesponsive episode (see section 2.3.3)</td>
</tr>
<tr>
<td>Clinical history of pertussis, measles, mumps or rubella infection – clinical history without laboratory confirmation cannot be taken as proof of immunity (even when an individual is proven to be immune to one or two of either measles, mumps or rubella, there is still the need for immunisation against the other/s, see the relevant chapters)</td>
</tr>
<tr>
<td>Prematurity, but an otherwise well infant – it is particularly important to immunise these children, who are likely to suffer severe illness if infected; immunisation is recommended at the usual chronological age (see ‘Preterm and low birthweight infants’ in section 4.2.1)</td>
</tr>
<tr>
<td>Stable neurological conditions, such as cerebral palsy or Down syndrome</td>
</tr>
<tr>
<td>Contact with an infectious disease</td>
</tr>
<tr>
<td>Egg allergy, including anaphylaxis, is not a contraindication to MMR vaccine (see section 11.6.3) or influenza vaccine (see section 10.6.3)</td>
</tr>
<tr>
<td>Family history of vaccine reactions</td>
</tr>
<tr>
<td>Family history of seizures</td>
</tr>
<tr>
<td>Family history of sudden unexpected death in infancy (SUDI)</td>
</tr>
<tr>
<td>Child’s mother or household member is pregnant or immunocompromised</td>
</tr>
</tbody>
</table>
2.1.5 Spacing of doses

In general, follow the recommendations in the manufacturers’ data sheets.

Principles for spacing of doses of the same vaccine

The immune response to a series of vaccines depends on the time interval between doses. The general rule is for a minimum of four weeks between doses of a primary series; however, the immune response may be better with longer intervals. A repeat dose of the same vaccine given less than four weeks after the previous dose may result in a reduced immune response. Specific recommendations for a rapid schedule by the manufacturer may apply for some vaccines.

Generally, a minimum interval of four to six months between priming dose(s) and the booster dose allows affinity maturation of memory B cells, and thus higher secondary responses (see section 1.1).

It is not necessary to repeat a prior dose if the time elapsed between doses is more than the recommended interval.

Spacing of different vaccines

Two or more parenterally administered live vaccines may be given at the same visit; for example, MMR and VV. However, when given at different visits, a minimum interval of four weeks is recommended. This interval is to avoid the response to the second vaccine being diminished due to interference from the response to the first vaccine. **Note that no interval is required between administration of bacillus Calmette–Guérin (BCG) and rotavirus vaccines.**

Unless there is a specific recommendation against it, an inactivated or subunit vaccine can be administered either simultaneously or at any time before or after a different inactivated, subunit or live vaccine.
Concurrent administration of vaccines

Best practice is to follow the Schedule. Changing the timing of visits or increasing the number of visits to avoid multiple injections delays protection against potentially serious diseases and may also lead to incomplete immunisation.

Where a number of different injectable vaccines are given on the same day, they must be administered in separate syringes, at different sites.

2.1.6 Catch-up programmes for unimmunised or partially immunised children

The objective of a catch-up programme is to complete a course of vaccinations that provides adequate protection. Catch-up programmes should be based on documented evidence of previous vaccination (eg, the child’s Well Child Tamariki Ora My Health Book, NIR or overseas immunisation records).

When children have missed vaccine doses, it is important to bring them up to date as quickly as possible. Where more than one vaccine is overdue, it is preferable to give as many as possible at the first visit. For children aged 15 months and older, MMR is the priority.

See Appendix 2 for determining catch-up requirements and planning a catch-up programme.

If the vaccinator is uncertain about how to plan a catch-up programme, they should contact the local immunisation coordinator, IMAC, medical officer of health or public health service.

Once catch-up is achieved, the child should continue as per the Schedule.
Vaccination of children with inadequate vaccination records

Children without a documented history of vaccination are recommended to have a full course of vaccinations appropriate for their age. In cases of doubt, it is safe to repeat vaccine doses: it is preferable for the individual to receive an unnecessary dose than to miss out a required dose(s) and not be fully protected.

2.1.7 Adult vaccination (aged 18 years and older)

Whenever adults are seen in general practice or by immunisation providers, there is an opportunity to ensure they have been adequately protected against the following diseases and have received at least a primary immunisation course as described in Table 2.4. If the requisite number of doses has not been received, catch-up vaccination is recommended and funded (see Appendix 2).

Women of childbearing age should know whether or not they are immune to rubella (see chapter 18) and varicella (see chapter 21).

Table 2.4: Primary immunisation requirements for adults (funded)

<table>
<thead>
<tr>
<th>Disease</th>
<th>Number of vaccine doses</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tetanus</td>
<td>3 doses</td>
</tr>
<tr>
<td>Diphtheria</td>
<td>3 doses</td>
</tr>
<tr>
<td>Poliomyelitis</td>
<td>3 doses</td>
</tr>
<tr>
<td>Measles, mumps, rubella</td>
<td>2 doses</td>
</tr>
<tr>
<td>HPV (aged 26 years and under)</td>
<td>3 doses*</td>
</tr>
</tbody>
</table>

* Individuals who were under age 27 years when they commenced HPV vaccination are currently funded to complete the 3-dose course, even if they are older than 27 years when they complete it.

See Table 2.5 for adult vaccination recommendations, including vaccinations recommended for at-risk groups (funded vaccines are in the shaded boxes). See also chapter 4 ‘Immunisation of special groups’ for information about immunisation during pregnancy and lactation (section 4.1), of immunocompromised individuals (section 4.3), of immigrants and refugees (section 4.4), for travel (section 4.5), and for those with occupational and other risk factors (section 4.6).
Table 2.5: Adult (≥18 years) vaccination recommendations, excluding travel requirements

<table>
<thead>
<tr>
<th>Vaccine</th>
<th>Recommended and funded</th>
<th>Recommended but not funded</th>
</tr>
</thead>
<tbody>
<tr>
<td>Hib (chapters 4 and 6)</td>
<td>(Re-)vaccination of patients post-haematopoietic stem cell transplant (HSCT) or chemotherapy; pre- or post-splenectomy or with functional asplenia; pre- or post-solid organ transplant, pre- or post-cochlear implants, renal dialysis and other severely immunosuppressive regimens</td>
<td></td>
</tr>
<tr>
<td>Hepatitis A (chapter 7)</td>
<td>Transplant patients Close contacts of hepatitis A cases&lt;sup&gt;a&lt;/sup&gt;</td>
<td>Patients with chronic hepatitis B or C infection; men who have sex with men; adults at occupational risk</td>
</tr>
<tr>
<td>Hepatitis B (chapter 8)</td>
<td>Household or sexual contacts of patients with acute or chronic HBV infection HIV-positive patients Hepatitis C-positive patients Following non-consensual sexual intercourse Following immunosuppression&lt;sup&gt;b&lt;/sup&gt; Solid organ transplant patients Post-HSCT patients Following needle-stick injury Dialysis patients Liver or kidney transplant patients</td>
<td>Non-immune adults at risk including occupational or other risk factors</td>
</tr>
<tr>
<td>HPV (chapter 9)</td>
<td>Individuals aged 18–26 years&lt;sup&gt;c,d&lt;/sup&gt; Individuals aged 18–26 years&lt;sup&gt;c,d&lt;/sup&gt; with confirmed HIV infection transplant (including stem cell) patients an additional dose post-chemotherapy</td>
<td>Adults ≥27 years&lt;sup&gt;c,d,e&lt;/sup&gt; who have had little previous exposure to HPV and are now likely to be exposed who are men who have sex with men with HIV</td>
</tr>
<tr>
<td>Annual influenza vaccine (chapter 10)</td>
<td>Pregnant women Individuals aged 65 years and older Individuals aged under 65 years with eligible conditions</td>
<td>All other adults</td>
</tr>
</tbody>
</table>

Continued overleaf
<table>
<thead>
<tr>
<th>Vaccine</th>
<th>Recommended and funded</th>
<th>Recommended but not funded</th>
</tr>
</thead>
<tbody>
<tr>
<td>MMR (chapters 11, 13 and 18)</td>
<td>Any individual susceptible to any one of these three diseases (Re-)vaccination following immunosuppression&lt;sup&gt;b&lt;/sup&gt;</td>
<td></td>
</tr>
<tr>
<td>MenCCV and MCV4-D (chapters 4 and 12)</td>
<td>For patients who are pre- or post-splenectomy or with functional asplenia; with HIV; with complement deficiency (acquired, including monoclonal antibody therapy against C5, or inherited); who are pre- or post-solid organ transplant Close contacts of meningococcal cases&lt;sup&gt;a&lt;/sup&gt; HSCT (bone marrow transplant) patients Patients following immunosuppression&lt;sup&gt;b&lt;/sup&gt;</td>
<td>Young adults in communal accommodation Laboratory personnel routinely exposed to <em>N. meningitidis</em></td>
</tr>
<tr>
<td>Pertussis-containing vaccine (chapters 4 and 14)</td>
<td>Tdap for pregnant women from 28 to 38 weeks’ gestation of every pregnancy Tdap for (re-)vaccination of patients who are post-HSCT or chemotherapy; pre- or post-splenectomy; pre- or post-solid organ transplant, renal dialysis and other severely immunosuppressive regimens</td>
<td>Tdap instead of Td if likely to be in contact with infants aged under 12 months</td>
</tr>
<tr>
<td>PCV13 and 23PPV (chapters 4 and 15)</td>
<td>(Re-)vaccination of patients with HIV; pre- or post-HSCT&lt;sup&gt;i&lt;/sup&gt; or chemotherapy&lt;sup&gt;j&lt;/sup&gt; pre- or post-splenectomy or with functional asplenia; pre- or post-solid organ transplant; renal dialysis; complement deficiency (acquired or inherited); cochlear implants; primary immune deficiency</td>
<td>PCV13 followed by 23PPV for those with certain conditions PCV13 followed by 23PPV for those aged 65 years or older</td>
</tr>
<tr>
<td>IPV (chapter 16)</td>
<td>Any unvaccinated or partially vaccinated individual (Re-)vaccination following immunosuppression&lt;sup&gt;b&lt;/sup&gt;</td>
<td></td>
</tr>
<tr>
<td>Td (chapters 5 and 19)</td>
<td>Td for susceptible individuals (including following immunosuppression); boosters&lt;sup&gt;a&lt;/sup&gt; at 45 and 65 years; boosting of patients with tetanus-prone wounds</td>
<td>Tdap instead of Td if likely to be in contact with infants aged under 12 months</td>
</tr>
</tbody>
</table>

*Continued overleaf*
<table>
<thead>
<tr>
<th>Vaccine</th>
<th>Recommended and funded</th>
<th>Recommended but not funded</th>
</tr>
</thead>
<tbody>
<tr>
<td>Varicella (chapter 21)</td>
<td>Non-immune patients:</td>
<td>Susceptible adults</td>
</tr>
<tr>
<td></td>
<td>• with chronic liver disease who may need a transplant in the future</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• with deteriorating renal function before transplantation</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• prior to solid organ transplant</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• prior to any elective immunosuppressionb</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• for post-exposure prophylaxis of immune-competent hospital in-patients</td>
<td></td>
</tr>
<tr>
<td>Patients at least 2 years after bone marrow transplant^h</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Patients at least 6 months after completion of chemotherapy^h</td>
<td></td>
<td></td>
</tr>
<tr>
<td>HIV-positive patients who are non-immune to varicella, with mild or moderate immunosuppression^h</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Patients with inborn errors of metabolism at risk of major metabolic decompensation, with no clinical history of varicella</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Household contacts of paediatric patients who are immunocompromised or undergoing a procedure leading to immunocompromise, where the household contact has no clinical history of varicella</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Household contacts of adult patients who have no clinical history of varicella and who are severely immunocompromised or undergoing a procedure leading to immunocompromise, where the household contact has no clinical history of varicella</td>
<td>Continued overleaf</td>
<td></td>
</tr>
</tbody>
</table>
### Vaccine

<table>
<thead>
<tr>
<th>Vaccine</th>
<th>Recommended and funded</th>
<th>Recommended but not funded</th>
</tr>
</thead>
</table>
| HZV (chapter 22) | From 1 April 2018, 1 dose of HZV is funded for:  
- individuals at age 65 years, or  
- catch-up of individuals aged 66–80 years, inclusive (the catch-up programme ceases on 31 March 2020). | HZV may be considered, but is not funded, for individuals aged 50–64 years who are:  
- at increased risk of shingles and who may benefit from being vaccinated earlier than the routine schedule  
- household contacts of an immunosuppressed individual. |

---

a Only 1 dose of vaccine is funded for close contacts.
b Note that the period of immunosuppression due to steroid or other immunosuppressive therapy must be longer than 28 days.
c Individuals who started with HPV4 may complete their remaining doses with HPV9.
d Individuals who were <27 years when they commenced HPV vaccination are currently funded to complete the 3-dose course, even if they are ≥27 years when they complete it.
e HPV9 vaccine is registered for use in females aged 9–45 years and in males aged 9–26 years. However, there are no theoretical concerns that the efficacy or safety of HPV vaccine in males up to the age of 45 years will differ significantly from females of the same age or younger males.
f PCV13 is funded pre- or post-HSCT or chemotherapy. 23PPV is only funded post-HSCT or chemotherapy.
g The administration charge for the Td booster is not funded, although the vaccine is free.
h On the advice of their specialist.

---

## 2.2 Vaccine administration

### 2.2.1 Minimising pain and distress at the time of vaccination

The WHO's Strategic Advisory Group of Experts on Immunization (SAGE) key recommendations for minimising pain and distress at the time of vaccination are:\(^4\)

- do not aspirate (draw back) when giving vaccines
- administer vaccines from the least to the most painful for all ages
- breastfeed before and during vaccine injection
• position (hold the infant/young child, individuals aged 3 years and older should sit up, parental presence)
• for infants, give oral rotavirus vaccine before injections (the vaccine contains sucrose that can reduce pain)
• use neutral words at the time of vaccination; avoid language that increases anxiety
• provide appropriate distractions
• consider using topical anaesthetics (only if the cost is acceptable to the family).

See also section 2.3.2 and the IMAC factsheet *Mitigating Vaccination Pain and Distress* (available at www.immune.org.nz/resources/written-resources).

### 2.2.2 Preparing for vaccine administration

**Key points for administering injectable vaccines**

Vaccines should not be mixed in the same syringe, unless the prescribing information sheet specifically states it is permitted or essential (eg, DTaP-IPV-HepB/Hib).

Careful use of a longer needle will cause less damage than a short needle.

To avoid tracking, make sure all the vaccine has been injected before smoothly withdrawing the needle.

Correct vaccine administration is important, and vaccinators have a responsibility to see that vaccines are given:

• in the optimal site
• using the appropriate needle size for vaccine effectiveness and patient safety.

The use of alternative sites will be based on professional judgement, including knowledge of the potential risks at each site and recommendations in the manufacturer’s data sheet.

The guidelines below will help to make the experience less distressing for the individual, parent/guardian and/or whānau, and vaccinator.
### Table 2.6: Guidelines for vaccine administration

<table>
<thead>
<tr>
<th>Preparation</th>
<th>Immunisation event</th>
</tr>
</thead>
<tbody>
<tr>
<td>Vaccinate in a private and appropriate setting.</td>
<td>Draw up injections out of sight, if possible. Medical paraphernalia is commonplace to vaccinators, but it may heighten the anxiety of some individuals.</td>
</tr>
<tr>
<td>Prepare the area/room layout to suit the vaccinator and vaccination event.</td>
<td>Ensure the individual or parent/guardian has had the opportunity to discuss any concerns and has given informed consent.</td>
</tr>
<tr>
<td>Be familiar with the vaccines (eg, their correct preparation, administration and the potential for adverse events).</td>
<td>Be prepared to include other family members and whānau in the discussion, and explain to older children accompanying infants why the injections are being given and what will happen.</td>
</tr>
<tr>
<td>Be aware of the individual’s immunisation history (eg, submit an NIR status query if the history is unknown).</td>
<td>Give the appropriate immunisations due and advise when the next immunisation event is due.</td>
</tr>
<tr>
<td>Ensure there are age-appropriate distractions available.</td>
<td>For babies, suggest that the mother breastfeeds baby before, during and after immunisation. For children, sit them upright and talk quietly to the child before and during immunisation. Make eye contact and explain what is going to happen. Even when a child is unable to understand the words, an unhurried, quiet approach has a calming effect and reassures the parent/guardian. See also section 2.3.2.</td>
</tr>
<tr>
<td>Ensure the relevant immunisation health education resources are available.</td>
<td>Give written and verbal advice to the individual and parent/guardian. The advice should cover what may be expected after immunisation, and what to do in the event of an adverse event, along with advice on when to notify the vaccinator.</td>
</tr>
</tbody>
</table>
Removal of air bubbles

Advice for removal of air in the syringe before vaccine administration is dependent on the vaccine presentation. See Table 2.7.

Table 2.7: Guidelines for management of air bubbles in a vaccine syringe

<table>
<thead>
<tr>
<th>Vaccine presentation</th>
<th>Management of air bubbles</th>
</tr>
</thead>
<tbody>
<tr>
<td>Vaccines supplied in a prefilled syringe with a fixed needle (eg, Influvac)</td>
<td>Do not expel the air</td>
</tr>
<tr>
<td>Vaccines supplied in a prefilled syringe without a fixed needle (eg, Gardasil 9)</td>
<td>Add an appropriate administration needle</td>
</tr>
<tr>
<td></td>
<td>Do not expel the air</td>
</tr>
<tr>
<td>Vaccines supplied diluted in a vial (eg, HBvaxPRO)</td>
<td>Draw up the entire vaccine volume into a syringe</td>
</tr>
<tr>
<td></td>
<td>Expel the air until the vaccine is at the level of the syringe hub, then change the needle</td>
</tr>
<tr>
<td></td>
<td>Do not expel the air contained in the new needle</td>
</tr>
<tr>
<td>Vaccines supplied as diluent and powder/pellet requiring reconstitution (eg, Infanrix-hexa, Priorix)</td>
<td>Reconstitute the vaccine correctly</td>
</tr>
<tr>
<td></td>
<td>Draw up the entire vaccine volume into a syringe</td>
</tr>
<tr>
<td></td>
<td>Expel the air until the vaccine is at the level of the syringe hub, then change the needle</td>
</tr>
<tr>
<td></td>
<td>Do not expel the air contained in the new needle</td>
</tr>
</tbody>
</table>

Skin preparation

Skin preparation or cleansing when the injection site is clean is not necessary. However, if an alcohol swab is used, it must be allowed to dry for at least two minutes, otherwise alcohol may be tracked into the muscle, causing local irritation. Alcohol may also inactivate a live attenuated vaccine such as MMR.

A dirty injection site may be washed with soap and water and thoroughly dried before the immunisation event.
2.2.3 Route of administration

Needle angle, gauge and length

Where possible, vaccinators should refer to the vaccine data sheet (available on the Medsafe website: www.medsafe.govt.nz) for the route of administration.

Most Schedule vaccines (with the exception of MMR, VV and IPV, which are administered subcutaneously, and rotavirus, which is administered orally) are administered by intramuscular injection. Intramuscular injections should be administered at a 90 degree angle to the skin plane. The needle length used will be determined by the size of the limb and muscle bulk, whether the tissue is bunched or stretched, and the vaccinator’s professional judgement. BCG vaccine (which can only be administered by authorised vaccinators with BCG endorsement) is given by intradermal injection. See Table 2.8.

Table 2.8: Needle gauge and length, by site and age

<table>
<thead>
<tr>
<th>Age</th>
<th>Site</th>
<th>Needle gauge and length</th>
<th>Rationale</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td><strong>Intramuscular (IM) injection</strong></td>
</tr>
<tr>
<td>Birth</td>
<td>Vastus lateralis</td>
<td>23–25 G × 16 mm</td>
<td>Choice of needle length will be based on the vaccinator’s professional judgement.</td>
</tr>
<tr>
<td>6 weeks</td>
<td>Vastus lateralis</td>
<td>23–25 G × 16 or 25 mm</td>
<td></td>
</tr>
<tr>
<td>3–14 months</td>
<td>Vastus lateralis</td>
<td>23–25 G × 25 mm</td>
<td>A 25 mm needle will ensure deep IM vaccine deposition.</td>
</tr>
<tr>
<td>15 months to 3 years</td>
<td>Deltoid or Vastus lateralis</td>
<td>23–25 G × 16 mm</td>
<td>The vastus lateralis site remains an option in young children when the deltoid muscle bulk is small and multiple injections are necessary.</td>
</tr>
</tbody>
</table>

Continued overleaf
## Processes for safe immunisation

<table>
<thead>
<tr>
<th>Age</th>
<th>Site</th>
<th>Needle gauge and length</th>
<th>Rationale</th>
</tr>
</thead>
<tbody>
<tr>
<td>3–7 years</td>
<td>Deltoid</td>
<td>23–25 G × 16 mm</td>
<td>A 16 mm needle should be sufficient to effect deep IM deposition in the deltoid in most children.</td>
</tr>
<tr>
<td></td>
<td>Vastus lateralis (^a)</td>
<td>21–22 G × 25 mm</td>
<td></td>
</tr>
<tr>
<td>Older children</td>
<td>Deltoid (^b)</td>
<td>23–25 G × 16 mm, or</td>
<td>Most adolescents and adults will require a 25 mm needle to effect deep IM deposition.</td>
</tr>
<tr>
<td>(7 years and older),</td>
<td></td>
<td>23–25 G × 25 mm, or</td>
<td></td>
</tr>
<tr>
<td>adolescents</td>
<td></td>
<td>21–22 G × 38 mm</td>
<td></td>
</tr>
<tr>
<td>and adults</td>
<td>Vastus lateralis (^a)</td>
<td>21–22 G × 38 mm</td>
<td></td>
</tr>
</tbody>
</table>

### Subcutaneous injection

| Subcutaneous injection | Deltoid region of the upper arm | 25–26 G × 16 mm         | An insertion angle of 45 degrees is recommended. The needle should never be longer than 16 mm or inadvertent IM administration could result. |

### Intradermal injection: BCG vaccine – for authorised vaccinators with BCG endorsement

| Intradermal injection | Slightly above the insertion of the deltoid muscle on the lateral surface of the left arm. The arm should be gently but firmly supported. | Drawing-up: Tuberculin syringe (attach a drawing-up needle), or a single-use insulin syringe with a needle attached | Administering: If using a tuberculin syringe, change the needle to a sterile 26 G × 13 or 16 mm needle (no needle change required if using an insulin syringe) | The syringe should be held with the bevel uppermost, parallel with the skin of the arm. The bevel should be fully inserted but visible under the skin. Inject the vaccine slowly and gradually to form a white ‘bleb’ or wheal, then gradually withdraw the needle. |

---

\(^a\) Consideration may be given to the vastus lateralis as an alternative vaccination site, providing it is not contraindicated by the manufacturer’s data sheet.

\(^b\) For females weighing <60 kg use a 23–25 G × 16 mm needle; for 60–90 kg use a 23–25 G × 25 mm needle; for >90 kg use a 21–22 G × 38 mm needle. For adolescent and adult males, a 23–25 G × 25 mm needle is sufficient.\(^5,6\)
Intramuscular injection sites

Injectable vaccines should be administered in healthy, well-developed muscle, in a site as free as possible from the risk of local, neural, vascular and tissue injury. Incorrectly administered vaccines (incorrect sites and poor administration techniques) contribute to vaccine failure, injection site nodules or sterile abscesses, and increased local reactions.

Careful use of a longer needle will cause less damage than a shorter needle.

The recommended sites for intramuscular (IM) vaccines (based on proven uptake and safety data) are:

- the vastus lateralis muscle on the anterolateral thigh for infants aged under 15 months – the vastus lateralis muscle is large, thick and well developed in infants, wrapping slightly onto the anterior thigh
- either the vastus lateralis or deltoid site for children aged 15 months to 3 years – the choice will be based on the vaccinator’s professional judgement
- the deltoid muscle for older children, adolescents and adults.

The deltoid muscle is not routinely used in infants and young children aged under 15 months, due to the potential for deltoid or radial nerve injury. However, when there is no access to the vastus lateralis (eg, the infant is in a spica cast), the deltoid muscle is used to administer intramuscular vaccines.

The buttock should not be used for the administration of vaccines in infants or young children, because the buttock region is mostly subcutaneous fat until the child has been walking for at least 9 to 12 months. Use of the buttock is not recommended for adult vaccinations either, because the buttock subcutaneous layer can vary from 1 to 9 cm and IM deposition may not occur.

With older children and adults, consideration may be given to using the vastus lateralis as an alternative site to the deltoid, providing it is not contraindicated by the manufacturer’s data sheet.
Subcutaneous injection sites

A subcutaneous (SC) injection should be given into healthy tissue that is away from bony prominences and free of large blood vessels or nerves. The recommended site for subcutaneous vaccine administration is the upper arm (overlying the deltoid muscle).

The principles for locating the upper arm site for an SC injection are the same as for an IM injection. However, needle length is more critical than angle of insertion for subcutaneous injections. An insertion angle of 45 degrees is recommended and the needle should never be longer than 16 mm, or inadvertent IM administration could result. The thigh may be used for SC vaccines unless contraindicated by the manufacturer’s data sheet. See also Table 2.2 for information about thrombocytopenia and bleeding disorders.

Intradermal injections

The intradermal injection technique for BCG vaccine (see section 2.2.4) requires special training, and should only be performed by an authorised vaccinator with BCG endorsement (see Appendix 4).

Oral vaccine administration

The rotavirus vaccine is administered orally. Administer the entire contents of the oral applicator into the infant’s mouth, towards the inner cheek (see section A7.2.4). Do not inject oral vaccines.

For specific oral vaccine administration instructions, refer to the vaccine data sheet (available on the Medsafe website: www.medsafe.govt.nz).

2.2.4 Infant vaccination

Infants aged under 6 months do not need to be grasped or restrained as firmly as toddlers or older children. At this age, excessive restraint increases their fear as well as muscle tautness. The recommended positioning for an infant is in a cuddle hold with parent/guardian, breastfeeding as appropriate. The cuddle position offers better psychological support and comfort for both the infant and the parent/guardian, and the parent/guardian should be offered this position as a first choice (Figure 2.1).
If the parent/guardian is helping to hold the infant or child, ensure they understand what is expected of them and what will take place. Most vaccinators choose to administer all the injections due quickly and soothe the infant or child afterwards (see section 2.3.2 for soothing measures).

**Figure 2.1: The cuddle position for infants**

![Image of a caregiver holding an infant in a cuddle position.]

**Vastus lateralis**

To locate the injection site, undo the nappy, gently adduct the flexed knee and (see Figure 2.2):

1. find the greater trochanter
2. find the lateral femoral condyle
3. section the thigh into thirds and run an imaginary line from the centre of the lower marker to the centre of the upper marker (look for the dimple along the lower portion of the fascia lata).

The injection site is at the junction of the upper and middle thirds and slightly anterior to (above) the imaginary line, in the bulkiest part of the muscle.
The needle should be directed at a 90 degree angle to the skin surface and inserted at the junction of the upper and middle thirds. Inject the vaccine at a controlled rate. To avoid tracking, make sure all the vaccine has been injected before smoothly withdrawing the needle. Do not massage or rub the injection site afterwards. However, infants with a bleeding disorder may require firm pressure over the injection site without rubbing for at least 10 minutes.
**BCG vaccine (administered by authorised vaccinators with BCG endorsement)**

The reconstituted BCG vaccine is given by intradermal injection slightly above the insertion of the deltoid muscle on the lateral surface of the left arm. The infant’s arm should be gently but firmly supported (see Figure 2.3[a]). The syringe should be held with the bevel uppermost, parallel with the skin of the arm (see Figure 2.3[b]).

**Figure 2.3: Photos showing the infant BCG vaccination site, and how to support the infant’s arm and hold the syringe**

(a)  
(b)
Inject the vaccine slowly (see Figure 2.4[a]), then gradually withdraw the needle. The injection is given slowly to avoid leakage around the needle or vaccine being squirted. Safety glasses should be used to protect the eyes of those involved. If BCG vaccine is accidentally squirted into the eyes, wash them immediately with water. Following BCG vaccination a white weal should appear (see Figure 2.4[b]), which should subside in approximately 30 minutes. The vaccination site requires no swabbing or dressing.

**Figure 2.4: Photos showing the BCG vaccine being slowly injected, and a white weal appearing as the needle is gradually withdrawn**

(a)  
(b)

### 2.2.5 Young child vaccination (vastus lateralis or deltoid)

The choice between the two sites for IM injections from 15 months of age will be based on the vaccinator’s professional judgement, such as knowledge of the child and ease of restraint. Some vaccinators consider the vastus lateralis preferable for young children when the deltoid muscle bulk is small and because of the superficiality of the radial nerve. Discuss the options with the parent/guardian when making your decision. (See also ‘The 15-month event’ in section 2.2.7.)
The easiest and safest way to position and restrain a young child for a lateral thigh and/or deltoid injection is to sit the child sideways on their parent’s or guardian’s lap. The parent’s/guardian’s hand restrains the child’s outer arm and the child’s legs are either restrained between the parent’s/guardian’s legs or by placing a hand on the child’s outer knee or lower leg. Alternatively, the child may face their parent/guardian while straddling the parent’s/guardian’s legs (see Figures 2.5 and 2.6).

**Figure 2.5: Photos showing cuddle positions for vastus lateralis or deltoid injections in children**

![Cuddle Position 1](image1.jpg) ![Cuddle Position 2](image2.jpg)

(a) (b)

**Figure 2.6: Photo showing the straddle position for vastus lateralis or deltoid injections in children**

![Straddle Position](image3.jpg)
If using the straddle position, both the deltoid and vastus lateralis muscle are likely to be more tense or taut, and the injection may therefore be more painful.

2.2.6 Older child, adolescent and adult vaccination (deltoid)

The deltoid muscle is located in the lateral aspect of the upper arm. The entire deltoid muscle must be exposed to avoid the risk of radial nerve injury (an injection at the junction of the middle and upper thirds of the lateral aspect of the upper arm may damage the nerve) (see Figure 2.7).

**Figure 2.7: Surface landmarks and structures potentially damaged by intramuscular injection in the upper limb**


The volume injected into the deltoid should not exceed 0.5 mL in children and 1.0 mL in adults.

The vaccinee should be seated with their arm removed from the garment sleeve and hanging relaxed at their side. The vaccinator places their index finger on the vaccinee’s acromion process (the highest point on the shoulder) and their thumb on the vaccinee’s deltoid tuberosity (the lower deltoid attachment point).7

The injection site is at the axilla line, between these anatomical landmarks. The vaccine should be deposited at the bulkiest part of the muscle (Figure 2.8).
2.2.7 Multiple injections at the same visit

A well-prepared and confident vaccinator will reassure the parent/guardian or whānau that giving concurrent vaccines is a safe and appropriate practice, avoiding multiple visits.

When more than one vaccine is scheduled at the same visit, vaccinators are recommended to give all of the scheduled vaccines at that visit. This particularly applies to the 15-month event (see below), when four vaccines are scheduled.

Multiple vaccines should not be mixed in a single syringe unless specifically licensed and labelled for administration in one syringe. A different needle and syringe should be used for each injection.

The 15-month event

MMR, varicella, PCV and Hib vaccines are scheduled at the 15-month event. When giving these vaccines, it is preferable to give the live vaccines (MMR and VV) in separate limbs. The IM injections should be given in the vastus lateralis and the SC injections in the deltoid.
The recommended vaccine administration sequence and location is:

1. Hib: Left vastus (IM)
2. Varicella: Left deltoid (SC)
3. PCV: Right vastus (IM)
4. MMR: Right deltoid (SC).

If parents/guardians request to split the vaccines given at the 15-month event, then providers are advised to give MMR and VV at the first visit, followed by PCV and Hib at the second visit.

Note:

- There is a possible risk of the patient not returning for the second visit when the 15-month vaccines are split.

- If MMR and VV are not given at the same visit (concurrently), then there should be an interval of at least four weeks between them. This interval is to avoid the response to the second vaccine being diminished due to interference from the response to the first vaccine (see section 2.1.5).

See also the IMAC video ‘Four in a row – a best practice guide for multiple vaccinations’ (https://vimeo.com/195383691).

**Multiple injections in the same muscle**

When giving two injections to be given in the same limb, the vastus lateralis is preferred because of its greater muscle mass (see Figure 2.9). The injection sites should be on the long axis of the thigh and *separated by at least 2 cm* so that localised reactions will not overlap.

If multiple injections in the deltoid are required, the sites should be separated by at least 2 cm.⁸
2.3 Post-vaccination

2.3.1 Post-vaccination advice

Post-vaccination advice should be given both verbally and in writing. The advice should cover:

- which vaccines have been given and the injection sites, and whether the injections were IM or SC
- common vaccine responses following immunisation (see Table 2.9) and what to do if these occur (eg, measures for relieving fever, when to seek medical advice)
- when the individual or parent/guardian should contact the vaccinator if they are worried or concerned
- contact phone numbers (including after-hours phone numbers).
### Table 2.9: Expected vaccine responses

<table>
<thead>
<tr>
<th>Vaccine</th>
<th>Expected vaccine responses</th>
</tr>
</thead>
</table>
| DTaP- or Tdap-containing vaccine | Localised pain, redness and swelling at injection site  
Mild fever  
Being grizzly and unsettled  
Loss of appetite, vomiting, and/or diarrhoea  
Drowsiness  
Extensive limb swelling after the 4th or 5th dose of a DTaP-containing vaccine |
| Hib                      | Localised pain, redness and swelling at the injection site  
Mild fever  
Being grizzly and unsettled |
| Hepatitis B              | Very occasionally pain and redness at the injection site  
Nausea or diarrhoea |
| HPV                      | Fainting, especially adolescents – this is an injection reaction, not a reaction to the vaccine  
Localised discomfort, pain, redness and swelling at the injection site  
Mild fever  
Headache |
| Influenza                | Localised pain, redness and swelling at injection site  
Headache  
Fever |
| MMR                      | Measles component: Fever which lasts 1–2 days; rash (not infectious) 6–12 days after immunisation  
Mumps component: Parotid and/or submaxillary swelling 10–14 days after immunisation  
Rubella component: Mild rash, fever, lymphadenopathy, joint pain 1–3 weeks after immunisation |
| Pneumococcal             | Localised pain, redness and swelling at injection site  
Mild fever  
Irritability, sleep changes  
Loss of appetite |
| Rotavirus                | Diarrhoea and or vomiting may occur after the first dose  
Mild abdominal pain |
| Adult Td                 | Localised discomfort, redness and swelling at the injection site |
| Varicella                | Localised pain, redness and swelling at injection site  
Mild fever  
Mild rash, possibly at the injection site (2–5 lesions, appearing 5–26 days after immunisation) |
2.3.2 Recommendations for fever and pain management

The use of paracetamol or ibuprofen around the time of immunisation in anticipation of immunisation-related fever or localised pain occurring is not recommended. However, use of these medicines is recommended if the child is distressed due to fever or pain following immunisation.

Paracetamol use may lower the immune response to some vaccines.\(^9\) However, there is no evidence that this results in less protection against disease.

Health care providers are encouraged to discuss with parents possible immunisation responses and non-pharmaceutical management of fever or pain, as well as the role of medicines.

Fever

General fever-relieving measures include:

- giving extra fluids to drink (eg, more breastfeeds or water)
- reducing clothing if the baby is hot.

While a high fever alone does not need treatment, antipyretic analgesics (paracetamol or ibuprofen) may be used for distress or pain in a febrile child who has not responded to the cooling measures described above.

Pain management and soothing measures

For infants aged under 12 months, breastfeeding before, during and after the injection can provide comfort and pain relief.\(^4, 10\)

Give the rotavirus vaccine 1–2 minutes before the other immunisations; rotavirus vaccines contain sucrose that has been shown to reduce pain.\(^4, 10\) The infant can then be breastfed (where possible) or held comfortably while the other immunisations are given.

For infants aged under 6 months the 5 S’s (swaddling, side/stomach position, shushing, swinging and sucking) have been found to be effective for soothing and reducing pain after immunisations.\(^11\)
Using age-appropriate distraction has been shown to reduce pain and distress. Examples include showing an interesting or musical toy to an infant, or encouraging an older child to blow using a windmill toy or bubbles. Electronic games/phone games can be useful for older children and teenagers. Do not rub the injection site after the injection as it increases the risk of vaccine reactogenicity.

For infants and children, the use of a topical anaesthetic cream or patch has been found to be effective for immunisation pain management. Parents/guardians and those administering the vaccine should check the manufacturers’ recommendations before using topical anaesthetics. The correct dose for infants needs to be followed particularly carefully due to risk of methaemoglobinaemia. Topical anaesthetics may have a role in managing immunisation pain and anxiety, particularly for children who have had previous multiple medical interventions or needle phobias.

Following immunisation, if an infant or child is distressed by pain or swelling at the injection site, placing a cold, wet cloth on the area may help relieve the discomfort. Antipyretic analgesics (paracetamol or ibuprofen) may be used if the above measure does not relieve the child’s distress.

### 2.3.3 Anaphylaxis and emergency management

| All vaccinators must be able to distinguish anaphylaxis from fainting, anxiety, breath-holding spells and seizures. |

Anaphylaxis is a very rare, unexpected and potentially fatal allergic reaction. It develops over several minutes and usually involves multiple body systems. Unconsciousness is rarely the sole manifestation and only occurs as a late event in severe cases. A strong central pulse (eg, carotid) is maintained during a faint (vasovagal syncope), but not in anaphylaxis.

In general, the more severe the reaction, the more rapid the onset. Most life-threatening adverse events begin within 10 minutes of vaccination. The intensity usually peaks at around one hour after onset. Symptoms limited to only one system can occur, leading to delay in diagnosis. Biphasic reactions, where symptoms recur 8 to 12 hours after onset of the original attack, and prolonged attacks lasting up to 48 hours have been described. All patients with anaphylaxis should be hospitalised.
Signs of anaphylaxis

Anaphylaxis is a severe adverse event of rapid onset, characterised by circulatory collapse. In its less severe (and more common) form, the early signs are generalised erythema and urticaria with upper and/or lower respiratory tract obstruction. In more severe cases, limpness, pallor, loss of consciousness and hypotension become evident, in addition to the early signs. Vaccinators should be able to recognise all of the signs and symptoms of anaphylaxis given in Table 2.10.

<table>
<thead>
<tr>
<th>Table 2.10: Signs and symptoms of anaphylaxis</th>
</tr>
</thead>
<tbody>
<tr>
<td>Signs and symptoms</td>
</tr>
<tr>
<td>Early warning signs (within a few minutes)</td>
</tr>
<tr>
<td>Dizziness, perineal burning, warmth, pruritus, flushing, urticaria, nasal congestion, sneezing, lacrimation, angioedema</td>
</tr>
<tr>
<td>Hoarseness, nausea, vomiting, substernal pressure</td>
</tr>
<tr>
<td>Laryngeal oedema, dyspnoea, abdominal pain</td>
</tr>
<tr>
<td>Life-threatening symptoms (from soon after the injection up to 20 minutes after)</td>
</tr>
<tr>
<td>Bronchospasm, stridor, collapse, hypotension, dysrhythmias</td>
</tr>
</tbody>
</table>

There is no place for conservative management of anaphylaxis. Early administration of adrenaline is essential (for more details, see Table 2.12).

Misdiagnosis of faints and other common causes of collapse as anaphylaxis may lead to inappropriate use of adrenaline. Misdiagnosis as a faint could also lead to a delay in the administration of adrenaline.

Vaccinators should therefore be able to distinguish anaphylaxis from fainting (vasovagal syncope), anxiety and breath-holding spells (see Table 2.11). Infants and babies rarely faint. Sudden loss of consciousness, limpness, pallor and vomiting (signs of severe anaphylaxis in children) should be presumed to be an anaphylactic reaction.
In adults and older children, the most common adverse event is a syncopal episode (fainting), either immediately or soon after vaccination. During fainting the individual suddenly becomes pale, loses consciousness and if sitting or standing will slump to the ground. Recovery of consciousness occurs within a minute or two. Fainting is sometimes accompanied by brief clonic seizure activity, but this generally requires no specific treatment or investigation if it is a single isolated event.

**Table 2.11: Distinguishing anaphylaxis from a faint (vasovagal reaction)**

<table>
<thead>
<tr>
<th>System</th>
<th>Faint</th>
<th>Anaphylaxis</th>
</tr>
</thead>
<tbody>
<tr>
<td>Onset</td>
<td>Usually before, at the time, or soon after the injection</td>
<td>Soon after the injection, but there may be a delay of up to 30 minutes</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Skin</th>
<th>Pale, sweaty, cold and clammy</th>
<th>Red, raised and itchy rash; swollen eyes and face; generalised rash</th>
</tr>
</thead>
<tbody>
<tr>
<td>Respiratory</td>
<td>Normal to deep breaths</td>
<td>Noisy breathing due to airways obstruction (wheeze or stridor); respiratory arrest</td>
</tr>
<tr>
<td>Cardiovascular</td>
<td>Bradycardia; transient hypotension</td>
<td>Tachycardia; hypotension; dysrrhythmias; circulatory arrest</td>
</tr>
<tr>
<td>Gastrointestinal</td>
<td>Nausea/vomiting</td>
<td>Abdominal cramps</td>
</tr>
<tr>
<td>Neurological</td>
<td>Transient loss of consciousness; good response once supine/flat</td>
<td>Loss of consciousness; little response once supine/flat</td>
</tr>
</tbody>
</table>

**Distinguishing a hypotonic-hyporesponsive episode from anaphylaxis**

A hypotonic-hyporesponsive episode is a shock-like state defined by the sudden onset of limpness (muscle hypotonia) and decreased responsiveness with pallor or cyanosis in infants and children aged under 2 years after immunisation.

A hypotonic-hyporesponsive episode can occur from immediately to 48 hours after immunisation, typically lasts less than 30 minutes, and resolves spontaneously. 12
A hypotonic-hyporesponsive episode is a recognised serious reaction to immunisation and should be reported to CARM (see section 1.6.3).

**Avoidance of anaphylaxis**

Before immunisation:

- ensure there are no known contraindications to immunisation
- if in doubt about administering the vaccine, consult the individual’s GP or a paediatrician.

> Individuals should remain under observation for 20 minutes following vaccination in case they experience an immediate adverse event requiring treatment.

**Emergency equipment**

Vaccinators, providers and quality managers are responsible for:

- ensuring emergency procedures are known by all staff
- practising emergency procedures regularly
- having an emergency kit (see Table 2.12) and adrenaline in every room where vaccinations/medications are given
- checking emergency kits regularly
- not giving vaccines when working alone.

Remember, events happen without warning. Appropriate emergency equipment must be immediately at hand whenever immunisations are given, and all vaccinators must be familiar with the practical steps necessary to save lives following an anaphylactic reaction (see Tables 2.12 and 2.13).
Table 2.12: Emergency equipment

An emergency kit should contain:
- adrenaline\(^*\) 1:1,000 (3 ampoules) and dosage chart
- syringes: 1.0 mL (a minimum of 3) (tuberculin not insulin, as the insulin needle is too short for IM injection)
- needles: a range of needle lengths and gauges, including 23 or 25 G \( \times \) 25 mm, 22 G \( \times \) 38 mm
- a range of airways, including paediatric sizes if vaccinating children.

Other emergency equipment required

It is also necessary to have on hand:
- an oxygen cylinder (check that it is filled)
- adult and paediatric bag valve mask resuscitator (eg, Ambu bag), oxygen tubing and a range of oxygen masks
- access to a telephone.

* The expiry date of the adrenaline and other medicines should be written on the outside of the emergency kit, and the kit should be checked every 4 weeks. Adrenaline is heat and light sensitive and should be stored appropriately. Adrenaline that has a brown tinge must be discarded.

The emergency kit may need to have additional equipment for non-clinical settings (see Appendix 4).

Hydrocortisone injection is used only under the direction of a medical practitioner (available on Medical Practitioner Supply Order).

Emergency management

An IM injection of 1:1,000 adrenaline is the mainstay of the treatment of anaphylaxis, and adrenaline should be universally available when vaccinating. A tuberculin syringe should be used to ensure the accuracy of measurement when drawing up small doses.

In an emergency situation there is no absolute contraindication to the use of adrenaline. It is, however, a very potent agent, and if used when anaphylaxis has not occurred or in excessive doses, adrenaline can cause dysrrhythmias, severe hypertension and left ventricular failure. Tissue necrosis can occur if the same injection site is used repeatedly.
Intravenous adrenaline should be administered by a medical practitioner with extreme caution, in small boluses, and under careful monitoring, and it is not appropriate as the first line of treatment of anaphylaxis.

**Table 2.13: Initial anaphylaxis response/management**

<table>
<thead>
<tr>
<th>CALL FOR HELP</th>
<th>send for professional assistance (ambulance, doctor). Never leave the individual alone.</th>
</tr>
</thead>
<tbody>
<tr>
<td>ASSESS</td>
<td>Assess responsiveness, and check Airway, Breathing, Circulation.</td>
</tr>
<tr>
<td></td>
<td>• If they are conscious, lie the individual down in the recovery position.</td>
</tr>
<tr>
<td></td>
<td>• If they are unconscious and breathing normally, lie the individual down in the</td>
</tr>
<tr>
<td></td>
<td>recovery position, ensuring that the airway is open.</td>
</tr>
<tr>
<td></td>
<td>• If they are unconscious and not breathing normally, institute standard procedures</td>
</tr>
<tr>
<td></td>
<td>for basic life support. If cardiorespiratory arrest occurs, administer age-appropriate CPR and life-support measures.</td>
</tr>
<tr>
<td>ADMINISTER ADRENALINE by deep intramuscular injection</td>
<td>dosage: 1:1,000 (adrenaline 1:1,000 = 1 mg/mL).</td>
</tr>
<tr>
<td></td>
<td>Adrenaline dosage for 1:1,000 formulation is 0.01 mL/kg up to a maximum of 0.5 mL.</td>
</tr>
<tr>
<td></td>
<td>If the individual’s weight is unknown, use the following guidelines:</td>
</tr>
<tr>
<td></td>
<td>• Infant aged under 1 year: 0.05–0.1 mL</td>
</tr>
<tr>
<td></td>
<td>• Child aged under 2 years: 0.1 mL</td>
</tr>
<tr>
<td></td>
<td>• Child 2–4 years: 0.2 mL</td>
</tr>
<tr>
<td></td>
<td>• Child 5–10 years: 0.3 mL</td>
</tr>
<tr>
<td></td>
<td>• Adolescent ≥11 years: 0.3–0.5 mL</td>
</tr>
<tr>
<td></td>
<td>• Adult: 0.5 mL</td>
</tr>
<tr>
<td></td>
<td>Route: deep IM. Where possible, administer in a non-injected limb, in either the</td>
</tr>
<tr>
<td></td>
<td>deltoid or vastus lateralis.</td>
</tr>
<tr>
<td></td>
<td>You can expect to see some response to the adrenaline within 1–2 minutes. If necessary, adrenaline can be repeated at 5–15-minute intervals, to a maximum of 3 doses, while waiting for assistance. Use alternate sites/limbs for additional doses.</td>
</tr>
<tr>
<td>ADMINISTER OXYGEN</td>
<td>at high flow rates where there is respiratory distress, stridor or wheeze.</td>
</tr>
<tr>
<td>IF HYPOTENSIVE, ELEVATE LEGS.</td>
<td></td>
</tr>
<tr>
<td>IF STRIDOR IS PRESENT, ELEVATE HEAD AND CHEST.</td>
<td></td>
</tr>
<tr>
<td>RECORD VITAL SIGNS</td>
<td>every 5–10 minutes. All observations and interventions need to be clearly documented in medical notes and should accompany the individual to hospital.</td>
</tr>
<tr>
<td>ADMIT TO HOSPITAL</td>
<td>all cases of anaphylaxis should be admitted to hospital for observation. Rebound anaphylaxis can occur 12–24 hours after the initial episode.</td>
</tr>
</tbody>
</table>

**Note:** Only medical practitioners should administer IV adrenaline.
**Ongoing management in hospital or by a medical practitioner**

Individuals who experience vaccine-related anaphylaxis should be admitted to hospital. If in an unstable or deteriorating condition, and not being transported by ambulance, the individual must be accompanied by the attending health professional so that treatment can be continued during transfer.

Hydrocortisone may be used as adjunctive medication. Nebulised salbutamol is helpful for bronchospasm. For further information, refer to the product data sheet.

Additional drugs that may be administered under the direction of a medical practitioner include:

- nebulised adrenaline: for laryngeal oedema
- bronchodilators: salbutamol 5 mg nebulised, to help reverse bronchospasm
- corticosteroids: prednisone 2 mg/kg (up to 40 mg) orally, or hydrocortisone 4 mg/kg IV, to help resolve tissue swelling (for young children and infants prednisolone syrup may be more appropriate).

Observation for a period of up to 24 hours after stabilisation of the individual’s condition is recommended due to the risk of late deterioration from delayed and biphasic reactions.

All anaphylaxis reactions should be reported to CARM (see section 1.6.3).

### 2.3.4 Documentation and insurance

Accurate documentation, including information on the NIR, School-Based Vaccination System (SBVS) and practice management system, (PMS) is essential. If the vaccinator has not kept accurate clinical records, it is difficult to prove what action/care was or was not taken/delivered if the patient notes are subject to legal scrutiny.
In addition to the information recorded on the NIR (see section 2.3.5), SBVS or PMS, information that should be collected in the patient’s clinical notes includes:

- confirmation that informed consent was given
- confirmation that the individual was observed for the recommended time and no adverse events occurred during the observation period (if an adverse event does occur, it is essential to document the action and treatment given and inform CARM – see section 1.6.3).

The vaccinator should also complete the relevant sections in the Well Child Tamariki Ora My Health Book and, where applicable, the child’s immunisation certificate (see Appendix 5), the Ministry of Health payment claim form (where applicable), and an NIR notification form if not using a computerised PMS.

**Indemnity insurance**

All vaccinators should carry indemnity insurance. Most employers have indemnity cover, but vaccinators do not have an automatic right to claim under that cover. Indemnity insurance should cover vaccinators/health professionals for disciplinary proceedings, coroners’ inquiries, and claims of negligence or error that may lead to injury, death or damage.

**2.3.5 The National Immunisation Register**

The National Immunisation Register (NIR) is a computerised information system that has been collecting immunisation information on New Zealand children since 2005 and from 2014 has been collecting some adult immunisation information. The purpose of the NIR is to facilitate immunisation delivery and provide an accurate record of an individual’s immunisation history.

The NIR also:

- provides a more accurate record of immunisation coverage rates regionally and nationally – this information assists with better programme planning to improve coverage rates and identify areas with lower immunisation rates
- collects information about the Schedule, HPV immunisations and some targeted programmes (eg, Tdap during pregnancy, BCG vaccine)
• collects information about influenza immunisations and high-risk adolescent and adult immunisations (since July 2014)
• enables health professionals to identify quickly and easily which vaccines an individual has received (especially if they have moved areas or changed health care providers) and any that are due or may have been missed
• enables individuals to have an accurate, up-to-date record of their immunisation history.

Managing the information on the National Immunisation Register

The information held on the NIR (collection, holding, use and disclosure) is governed by the Health Information Privacy Code 1994 and section 22F of the Health Act 1956 (see section 2.1.2).

The NIR’s privacy policy can be found on the Ministry of Health website (www.health.govt.nz/nir). The policy sets out the framework for data collection, storage, use and disclosure of health information held about identifiable individuals on the NIR.

Individuals or their parents/guardians may choose at any time not to have any health information collected on the register (ie, they can opt off the further collection of immunisation data). However, the NIR will retain the individual’s National Health Index (NHI) number, date of birth, DHB they are resident in, date of opt off, and any immunisation information recorded before opt off. The reason for retaining this information is to provide an accurate denominator for immunisation coverage calculations, and to prevent inappropriate recall and referral.

An individual’s immunisation information will be retained on the NIR for their whole life, plus a period of 10 years after their death.

Only authorised users have access to the information held on the NIR. Such a person is authorised to use and disclose NIR information in accordance with their function. Penalties for unauthorised disclosure of information could include the revocation of authorised user privileges, complaints to the Privacy Commissioner, civil proceedings, professional sanctions, and disciplinary action, up to and including termination of employment.
Information collected on the NIR includes:

- date of vaccination
- individual’s name
- individual’s NHI number
- individual’s date of birth
- secondary contact details
- parent/guardian details for children aged under 18 years
- vaccine type and number in the series
- batch number and expiry date
- injection site, injection route and needle length used
- provider name
- vaccinator’s name and title
- recall date (when applicable)
- adverse event data, once verified by CARM.

More information about privacy and informed consent can be found in section 2.1.2 and Appendix 3. Further information about the NIR can be found on the Ministry of Health website (www.health.govt.nz/nir).

The SBVS

The SBVS collects and manages the data for school immunisation programmes (eg, where public health nurses deliver the school year 7 and year 8 immunisation programmes). The information collected on the SBVS for the school immunisation programmes is then transferred to the NIR.

Not all DHBs use the SBVS software for managing their school-based programmes; however, all DHBs are required to record school-based vaccination events on the NIR regardless of whether they use the SBVS, another PMS or direct enter on to the NIR.
References


